Tuesday, November 8, 2016

BRIEF-Galectin Therapeutics Q3 loss per share $0.19

* Galectin Therapeutics Inc- on track for reporting of

top-line results in december of 2017 for nash-cx trial

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)